Form 4: Inmune Bio Director Granted 150,000 Stock Options

Inmune Bio, Inc. Director Marcia Allen was granted 150,000 stock options with an exercise price of $1.48, vesting monthly over three years.

Summary

• Marcia Allen, a Director of Inmune Bio, Inc. (INMB), was granted 150,000 stock options.
• The options have an exercise price of $1.48 per share.
• The grant date for these options was December 1, 2025.
• The options will vest pro rata on a monthly basis over three years, with full vesting occurring on the three-year anniversary of the grant date.
• The expiration date for these options is November 23, 2035.
• These options were granted under the Issuer's Second Amended and Restated 2021 Stock Incentive Plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice, aligning director interests with shareholders, but does not reflect new operational performance or strategic shifts.

Positives

• The grant of stock options to a director aligns management and director interests with shareholder value.
• The options have a long expiration date (November 23, 2035), providing ample time for potential value appreciation.

Negatives

• No immediate negative financial impact is indicated by this grant.

Risks

• The value of the options is dependent on the future stock price performance of Inmune Bio, Inc.
• If the stock price does not exceed the exercise price of $1.48, the options may expire worthless.

Future Outlook

The grant of stock options suggests a long-term incentive for the director, aligning their future performance with the company's stock appreciation over the vesting and exercise period.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and retention.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across many industries, including biotech, to align interests with shareholders.
• The vesting schedule of three years is typical for long-term incentive plans, comparable to practices at companies like Biogen or Amgen for similar roles, though specific grant sizes vary based on company size and individual responsibilities.

Corporate Governance

Related Party Transactions

• The option grant to a director is a related party transaction, representing standard compensation practice.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also potential for increased director alignment with shareholder value creation.
• Employees: No direct impact mentioned for general employees.

Next Steps

• The options will vest monthly over the next three years from the grant date of December 1, 2025.
• Marcia Allen may choose to exercise these options at any point after they vest and before their expiration date of November 23, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation package. While it aligns the director's interests with long-term shareholder value, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

Inmune Bio, INMB, stock options, director compensation, Form 4, insider transaction, equity grant, stock incentive plan